

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: November 9, 2002, 04:34:22 ; Search time 298 Seconds  
(without alignments)  
1435.838 Million cell updates/sec

Title: US-09-895-298A-83  
Perfect score: 1002  
Sequence: 1 MMNFQPPSKAWRASQMTTF.....HDGSLDLRSRVSQEGNPRA 190

Scoring table: BLOSUM62  
Xgapop 10.0 , Xgapext 0.5  
Ygapop 10.0 , Ygapext 0.5  
Fgapop 6.0 , Fgapext 7.0  
Delop 6.0 , Delext 7.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp  
-Q=/cgn2.1/USPTO\_spool/US09895298/runat\_06112002\_160415\_2322/app-query.fasta-1.327  
-DB=N\_Geneseq\_101002 -QFMT=fastap -SUFFIX=ring -MINMATCH=0.1 -LOOPEXT=0  
-LOOPEXT=0 -UNITS=bites -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi  
-LIST=45 -DOCALIGN=200 -THR\_SCORE=pct -THR\_MAX=100 -THR\_MIN=0 -ALIGN=15  
-MODE=LOCAL -OUTFMT=ptc -NOM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000  
-USER=US09895298 @CGN\_1\_1\_79\_@runat\_06112002\_160415\_2322 -NCPU=6 -ICPU=3  
-NO\_XLPXY -NO\_MMAP -LARGEQUERY -NEG\_SCORES=0 -WAIT -LONGLOG -DEV\_TIMEOUT=120  
-NARN\_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6 -FGAPEXT=7  
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N\_Geneseq\_101002.\*  
1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:\*  
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:\*  
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:\*  
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:\*  
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:\*  
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:\*  
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:\*  
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:\*  
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:\*  
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:\*  
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:\*  
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:\*  
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:\*  
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:\*  
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:\*  
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:\*  
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:\*  
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:\*  
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:\*  
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:\*  
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:\*  
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:\*  
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:\*  
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1002	100.0	1097	22	ABA08605	Human LAK-4p homol
2	1002	100.0	1097	22	AAK53221	Human polynucleoti
3	1002	100.0	1219	22	AAF82463	Human CASB6411-rel
4	1002	100.0	1312	22	AAK52237	Human polynucleoti
5	1002	100.0	1461	21	AAAF8402	Human secreted pro
6	1002	100.0	1813	22	AAH18131	Human cDNA sequenc
7	1002	100.0	1960	22	AAF82462	Human CASB6411-rel
8	1002	100.0	2243	21	AAA64684	cDNA encoding a hu
9	1002	100.0	2407	22	AAF82460	Human CASB6411 cDN
10	1002	100.0	2521	22	AAF82461	Alternatively spli
11	953	95.1	1194	23	ABV22463	Human prostate exp
12	953	95.1	1194	23	ABV25683	Human prostate exp
13	953	95.1	1194	23	ABV28278	Human prostate exp
14	620	61.9	470	22	AAH18591	Human breast cancer
15	614	61.3	501	22	AAH09919	Human breast cancer
16	391.5	39.1	777	22	AAH08034	Human cDNA clone (
17	391	39.0	617	23	ABV12915	Human prostate exp
18	387	38.6	286	23	ABV08852	Human prostate exp
19	315	31.4	233	22	AAH10187	Human breast cancer
20	306	30.5	197	22	AAH19767	Human breast cancer
21	293	29.2	2902	24	ABQ54905	Human ovarian anti
22	285	28.4	590	23	ABV34041	Human prostate exp
23	285	28.4	590	23	ABV42908	Human prostate exp
24	266	26.5	555	22	AAH20351	Human breast cancer
25	212	21.2	402	22	AAF65737	Novel human polynu
26	177	17.7	454	22	ABA58847	Human foetal liver
27	177	17.7	454	22	AAK07004	Human brain expres
28	177	17.7	454	22	AAK32745	Human bone marrow
29	177	17.7	454	22	AAH38558	Probe #7244 used t
30	177	17.7	454	24	ABS07543	Human genome-deriv
31	172	17.2	498	22	AAH11452	Human breast cancer
32	157	15.7	523	23	ABV03746	Human prostate exp
33	148	14.8	94	22	ABA71379	Human foetal liver
34	148	14.8	94	22	AAH19696	Human brain expres
35	148	14.8	94	22	AAK45716	Human bone marrow
36	148	14.8	94	22	AAH51641	Probe #20327 used
37	148	14.8	94	24	ABS19939	Human genome-deriv
38	124.5	12.4	545	20	AAAX20418	Human secreted pro
39	107.5	10.7	1633	22	AAAS21352	Human cDNA sequenc
40	104.5	10.4	2703	22	AAK94324	Human full-length
41	104.5	10.4	6391	22	AAAL26423	Human breast cancer
42	101.5	10.1	5929	23	ABH05865	Drosophila melanog
43	97	9.7	5027	23	AAAS92296	DNA encoding novel
44	93.5	9.3	1442	20	AAH13617	Enterococcus faeca
45	91	9.1	486	22	AAH84071	Pongo pygmaeus Olf

ALIGNMENTS

RESULT 1  
ABA08605  
ID ABA08605 standard; cDNA; 1097 BP.  
XX  
AC ABA08605;  
XX  
DT 11-JAN-2002 (first entry)  
XX  
DE Human LAK-4p homologue-encoding cDNA, SEQ ID NO:381.  
XX  
KW Human: cytokine; cell proliferation; cell differentiation; growth factor;  
KW haematopoiesis regulation; tissue growth; immunomodulator; activin;  
KW inhibitor; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
KW chronic inflammatory condition; proliferative retinopathy;  
KW atherosclerosis; coronary heart disease; arterial ischaemia;  
KW bone disorder; osteoporosis; vascular growth disorder;

KW tissue regeneration; wound healing; infection; immune disorder;  
KW cell culture; drug screening; gene therapy; antiinflammatory;  
KW antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
KW cytosatic; osteopathic; vasotropic; cardant; virucide; antibacterial;  
KW antifungal; vulnereary; antilucer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200157188-A2.  
XX  
PD 09-AUG-2001.  
XX  
XX 05-FEB-2001; 2001WO-US03800.  
XX  
XX 03-FEB-2000; 2000US-0496914.  
PR 27-APR-2000; 2000US-0560875.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Drmanac RT;  
XX  
DR WPI; 2001-457740/49.  
DR P-PSDB; ABB11361.  
XX  
XX  
PT Human proteins and DNA encoding sequences useful for preventing,  
PT treating or ameliorating a medical condition in a mammalian subject  
PT e.g. arthritis and cancer -  
XX  
PS Claim 1; Page 473; 1963pp; English.  
XX  
CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, thereby  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities, including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
CC thrombolytic activities; receptor or ligand activities; or may be  
CC involved in oncogenesis, cancer cell proliferation or metastasis.  
CC Depending on their biological activities, polypeptides and nucleotides of  
CC the invention are useful for preventing, treating or ameliorating medical  
CC conditions, e.g., by protein or gene therapy. Such conditions include  
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with  
CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.  
CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a cDNA encoding a  
CC novel human polypeptide of the invention.  
XX  
SQ Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Alignment Scores:  
Pred. No.: 1.69e-108 Length: 1097  
Score: 1002.00 Matches: 190

Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0

US-09-895-298A-83 (1-190) x ABA08605 (1-1097)

QY 1 MetMetAsnPhgeInProProSerIysAlaTrpArgAlaSerGlnMetThrPhePhe 20  
DB 269 ATGATGATATTCAGCCCTCCGAGCAAGCCGCGGCTTCACAGATGATGACTTCTTC 328  
QY 21 IlePheIeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 329 ATCTTCTTGCTCTTTTCCATCCTTCACCGGGCTTGTGCACCCCTGGCCATCACATC 388  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 389 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTGAGAGGTCTGCTCTTCATTCCAC 448  
QY 61 SerIleThrSerTrpIleAspThrLeuSerThrArgProGlyThrLeuTrpValValTrp 80  
DB 449 TCCATCTACAGCTGGATGCACACCTAAGTACAGCGCCTGGCTTACCTGTGGTGTGG 508  
QY 81 IleTyrArgAsnIeuIleGlySerValHisPhePheIleuThrLeuIleValLeu 100  
DB 509 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCTCACCCTCATTTGTGCTA 568  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlyArgLysIleMetIleArgLeuLeu 120  
DB 569 ATCATCACTATCTTTTACGCGCAGATCACAGAGGAAGATATATGAAGCGCTC 628  
QY 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140  
DB 629 CATGACGAGATCATTTAATGAGGGCAAAAGATTAATGTTCTGTATGAATAATTGATCAAG 688  
QY 141 LeuGlnAspMetCulLysLysAlaAsnProSerSerIeuValLeuGluArgGluVal 160  
DB 689 CTGCAGATATGAGAGAAGCAAAACCCAGCTCCTGTTCTGGAAGAGAGAGGTG 748  
QY 161 GluGluGlnGlyPheLeuHisLeuGlyLysIleAspGlySerLeuAspLeuArgSerArg 180  
DB 749 GAGCAACAAGGCTTTTTCGATTTGGGGGACATGATGCGAGTTGACTTGGCATCTAGA 808  
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190  
DB 809 AGATCACTTCAAGAAAGTAAATCCAAGGGCC 838  
RESULT 2  
AAK53221  
ID AAK53221 standard; cDNA; 1097 BP.  
XX AAK53221;  
AC  
XX 06-NOV-2001 (first entry)  
DT  
XX Human polynucleotide SEQ ID NO 2750.  
DE  
XX  
XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
KW nervous system disorder; arthritis; inflammation; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200157190-A2.  
XX  
PD 09-AUG-2001.  
XX  
XX 05-FEB-2001; 2001WO-US04098.  
PF  
XX 03-FEB-2000; 2000US-0496914.  
PR 27-APR-2000; 2000US-0560875.  
PR 20-JUN-2000; 2000US-0598075.

PR 19-JUL-2000; 2000US-0620325.  
PR 01-SEP-2000; 2000US-0654936.  
PR 15-SEP-2000; 2000US-0663561.  
PR 20-OCT-2000; 2000US-0693325.  
PR 30-NOV-2000; 2000US-0728422.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;  
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
PI Xue AJ, Yang Y, Wejrtman T, Goodrich R;  
XX  
DR WPI: 2001-476283/51.  
DR P-PSDB; AAM80088.  
XX  
PT Nucleic acids encoding polypeptides with cytokine-like activities,  
PT useful in diagnosis and gene therapy -  
XX  
PS Claim 1; Page 4962; 6221pp; English.  
XX  
CC The invention relates to polynucleotides (AAK51456-AAK53435) and the  
CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation.  
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666  
CC (AAM80020) are omitted as the relevant pages from the sequence listing  
CC were missing at the time of publication.  
XX  
SQ Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Alignment Scores:  
Pred. No.: 1.69e-108 Length: 1097  
Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0

US-09-895-298A-83 (1-190) x AAK53221 (1-1097)

QY 1 MetMetAsnPhenGlnProSerSerLysAlaTrpArgAlaSerGlnMetThrPhe 20  
DB 269 ATGATGAAATTTCAGCCTCCGAGCAAAAGCCTGGCGGCTCAGATGATGACTTCTTC 328

QY 21 IlePheLeuLeuPhePheProSerPhePhehGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 329 ATCTTCTTGCTCTTTTCCCATCTTCACCGGGGCTTGTGCACTGCGCATCACCATC 388

QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 389 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCATTAC 448

QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
DB 449 TCCATCTACAGCTGGATGCACACCTTAAGTACACGGGCTGGCTACCTGGGGTGGTTGG 508

QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrLeuIleValLeu 100  
DB 509 ATCTATCGGAACCTCATTTGGAAGGTGCACATCTTTTCATCTCACCCTCATTTGCTA 568

QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyValArgLysIleMetIleArgLeu 120  
DB 569 ATCATCACCTATCTTACTGGCAGATCACAGAGGGAAGATATGATTAAGGCTGCTC 628

QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140  
|||||

DB 629 CATGACGAGATCATTAATGAGGGCAAGATAAATGTTCCGTGATAGAAATATGATCAAG 688

QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerLeuValLeuGlnArgGlnVal 160  
|||||

DB 689 CTGCAGGATATGAGAGAAAGCAAAACCCAGCTCACTTGTCTGGAAAGGAGAGAGGTG 748

QY 161 GlnGlnGlnGlyPheLeuHisLeuGlyGlnHisAspGlySerLeuAspLeuArgSerArg 180  
|||||

DB 749 GAGCAACAAAGGCTTTTTCATTTTGGGGGAACATGATGGCAGTCTTGCGATCTAGA 808

QY 181 ArgSerValGlnGlnGlyAsnProArgAla 190  
|||||

DB 809 AGATCAGTTCAAGAAGGTATCCCAAGGCC 838

RESULT 3  
AAF82463  
ID AAF82463 standard; cDNA; 1219 BP.  
XX  
AC AAF82463;  
XX  
DT 29-JUN-2001 (first entry)  
XX  
DE Human CASB6411-related cDNA #2.  
XX  
KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
KW ovarian cancer; colon cancer; autoimmune disease; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key location/Qualifiers  
FT CDS 1..576  
FT /\*tag= a  
FT /partial  
FT /note="this sequence does not contain a start codon"  
XX  
PN WO200123417-A2.  
XX  
PD 05-APR-2001.  
XX  
PF 27-SEP-2000; 2000WO-EP09500.  
XX  
PR 30-SEP-1999; 99GB-0023154.  
PR 07-JUL-2000; 2000GB-0016839.  
XX  
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.  
XX  
XX Vinals De Bassols YC;  
PI  
DR WPI: 2001-316133/33.  
DR P-PSDB; AAB83082.  
XX  
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for  
PT prophylactic and therapeutic treatment of cancers, particularly ovarian  
PT and colon cancers, autoimmune diseases and related conditions -  
XX  
XX  
PS Claim 32; Page 66-67; 95pp; English.  
XX  
XX The present sequence is provided in a specification relating  
CC to CASB6411 polypeptides comprising a sequence having at least 70%  
CC identity to a sequence of 460 or 154 amino acids fully defined in  
CC the specification. CASB6411 polypeptides and polynucleotides are  
CC useful for treating a subject by immunoprophylaxis or therapy.  
CC The CASB6411 polypeptides are useful in diagnostics, and as  
CC vaccines for prophylactic and therapeutic treatment of cancers,  
CC particularly ovarian and colon cancers, autoimmune diseases and related  
CC conditions. CASB6411 polypeptides are also useful for the  
CC structure-based design of agonists, antagonists or inhibitors of the  
CC polypeptide.  
XX  
SQ Sequence 1219 BP; 346 A; 260 C; 275 G; 338 T; 0 other;

Alignment Scores:  
Pred. No.: 1.97e-108 Length: 1219

Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAF82463 (1-1219)

QY 1 MetMetAsnPhcglNProProSerSerlySAlaTrpArgAlaSerGlnMetMetThrPhePhe 20  
DB 4 ATGATGAATTCACGCTCCGAGCAAAAGCCCTGGCGGCTCCACAGATGATGACTTCTTC 63  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 64 ATCTTCTGCTCTTTTCCCATCTTTCACCCGGGCTTGTGACACCTGGCCATCACCATC 123  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 124 TGGAGATTGAAGCCTTCACCTGACGTGGCCCTTTGAGAGTCTGCTCTTCATTCCAC 183  
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
DB 184 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCTGGCTACCTGTGGGTTGTTGG 243  
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
DB 244 ATCTATCGGAACCTCATGTGAAGTGGACACTCTTTTCATCCACCCCATGTGCTG 303  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120  
DB 304 ATCATCACTATCTTTACTGGCAGATCACAGAGGGAAGATATGATTAAGGCTGCTC 363  
QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140  
DB 364 CATGAGCAGATCTTAATGAGGGCAAGATAAATGTTCCCTGATAGAAAATGTATCAAG 423  
QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160  
DB 424 CTGACAGATATGAGAAAGCAAAACCCACCTGCTGTCGAAAGAGAGAGAGTG 483  
QY 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180  
DB 484 GAGCAACAAGCCTTTTTCATTTGGGGGACATGATGCAAGTCTTGACCTTGCGATCTAGA 543  
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190  
DB 544 AGATCACTTCAACAAGGTAATCCAAAGGGCC 573

RESULT 4

AAK52237  
ID AAK52237 standard; cDNA; 1312 BP.

AC AAK52237;

DT 06-NOV-2001 (first entry)

XX Human polynucleotide SEQ ID NO 782.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;

KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;

KW tissue growth factor; immunomodulatory; cancer; leukaemia;

XX nervous system disorder; arthritis; inflammation; ss.

OS Homo sapiens.

PN WO200157190-A2.

PD 09-AUG-2001.

XX 05-FEB-2001; 2001WO-US04098.  
PF 03-FEB-2000; 2000US-0496914.  
PR 27-APR-2000; 2000US-0560875.  
PR

PR 20-JUN-2000; 2000US-0598075.  
PR 19-JUL-2000; 2000US-0620325.  
PR 01-SEP-2000; 2000US-0654936.  
PR 15-SEP-2000; 2000US-0663561.  
PR 20-OCT-2000; 2000US-0693325.  
PR 30-NOV-2000; 2000US-0728422.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;  
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;  
XX  
DR WPI; 2001-476283/51.  
DR P-PSDB; AAM79104.

XX Nucleic acids encoding polypeptides with cytokine-like activities,  
PT useful in diagnosis and gene therapy -  
PS Claim 1; Page 2615-2616; 6221pp; English.

XX The invention relates to polynucleotides (AAK51456-AAK53435) and the  
CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhbin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation.  
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666  
CC (AAM80020) are omitted as the relevant pages from the sequence listing  
CC were missing at the time of publication.

XX Sequence 1312 BP; 370 A; 286 C; 287 G; 369 T; 0 other;

Alignment Scores:

Pred. No.: 2.19e-108 Length: 1312  
Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAK52237 (1-1312)

QY 1 MetMetAsnPhcglNProProSerSerlySAlaTrpArgAlaSerGlnMetMetThrPhePhe 20  
DB 294 ATGATGAATTCACGCTCCGAGCAAAAGCCCTGGCGGCTCCACAGATGATGACTTCTTC 353  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 354 ATCTTCTGCTCTTTTCCCATCCCTTCACCGGGTCTGTGACACCTGGCCATCACCATC 413  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 414 TGGAGATTGAAGCCTTCACCTGACGTGGCCCTTTTCAGAGTCTGCTCTTCATTCCAC 473  
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
DB 474 TCCATCTACAGCTGGATGCACACCCCTAAGTACACGGCCTGGCTACCTGTGGTGTGG 533  
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
DB 534 ATCTATCGGAACCTCATGTGAAGTGGACACTCTTTTCATCCACCCCATGTGCTTA 593  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120  
DB 594 ATCATCACTATCTTTACTGGCAGATCACAGAGGGAAGATATGATTAAGGCTGCTC 653  
QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140

```
Db 654 CATGAGCAGATCATTAATGAGGGCAAAAGATAAATGTTCTGATAGAAAATGATCAAG 713
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160
Db 714 CTGCAGGATATGGAGAGAAACCAACCCAGCTCACTGTTCTGTGAAGAAGAGAGAGTG 773
QY 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
Db 774 GAGCAACAAGGCTTTTGGCATTTGGGGGAAACATGATGGCAGTCTTGACTTGGCATCTAGA 833
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190
Db 834 AGATCAGTTCAGAAGTAATCCCAAGGCC 863

RESULT 5
AAA78402
ID AAA78402 standard; cDNA; 1461 BP.
XX
XX AAA78402;
AC
XX
XX 20-NOV-2000 (first entry)
DT
XX
XX Human secreted protein gene 22 SEQ ID NO:32.
DE
XX
XX Human; secreted protein; cytosstatic; antianaemic; antidiabetic;
KW antinflammatory; ophthalmological; antirheumatic; antiarthritic;
KW antipsoriatic; antiangiogenic; cardiant; anti-HIV; nootropic;
KW neuroprotective; antimicrobial; antiparkinsonian; cancer;
KW immune system disorder; angiogenesis; hyperproliferative disorder;
KW cardiovascular disorder; apoptosis; neurological disease;
KW infectious disease; wound healing; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200035937-A1.
PN
XX
XX 22-JUN-2000.
PD
XX
XX 16-DEC-1999; 99WO-US29950.
PF
XX
XX 17-DEC-1998; 98US-0112809.
PR
XX
XX 18-DEC-1998; 98US-0113006.
PX
XX
XX (HUMA-) HUMAN GENOME SCI INC.
PA
XX
XX Ruden SM, Edner R, Rosen CA, Endress GA, Soppet DR, Ni J;
PI Duan DR, Moore PA, Shi Y, Lafleur DW, Olsen HS, Florence K;
PI
XX
XX WPI: 2000-431566/37.
DR
XX
XX P-PSDB; AAB24458.
DR
XX
XX
XX
XX Forty seven human nucleic acids encoding secreted proteins, useful in
PT the treatment, prevention and diagnosis of cancers, disorders of the
PT immune system, angiogenesis disorders, neurological diseases and
PT hyperproliferative disorders -
XX
XX Claim 1; Page 457-458; 562pp; English.
PS
XX
XX
XX The polynucleotide sequence given in AAA78381 to AAA78432 encode the
CC human secreted proteins given in AAB24437 to AAB24604. Human secreted
CC proteins have activities based on the tissues and cells the genes are
CC expressed in. Examples of activities include: cytosstatic; antianaemic;
CC antidiabetic; antinflammatory; ophthalmological; antirheumatic;
CC antiarthritic; antipsoriatic; antiangiogenic; cardiant; anti-HIV;
CC nootropic; neuroprotective; antimicrobial and antiparkinsonian.
CC Human secreted protein polynucleotides, polypeptides, antagonists and/or
CC agonists may be useful in treating, preventing, and/or diagnosing other
CC diseases, disorders, and/or conditions such as: (a) cancers; (b)
CC disorders of the immune system; (c) angiogenesis disorders; (d)
CC hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases
CC associated with increase apoptosis; (g) neurological diseases; and
CC (h) infectious diseases. They are also used to promote wound healing.
```

```
CC AAA78372 to AAA78380 and AAB24436 represent sequences used in the
CC exemplification of the present invention.
XX
XX Sequence 1461 BP; 428 A; 312 C; 324 G; 397 T; 0 other;
SQ
XX
XX Alignment Scores:
XX Pred. No.: 2.56e-108 Length: 1461
XX Score: 1002.00 Matches: 190
XX Percent Similarity: 100.00% Conservative: 0
XX Best Local Similarity: 100.00% Mismatches: 0
XX Query Match: 100.00% Indels: 0
XX DB: 21 Gaps: 0
XX
XX US-09-895-298a-83 (1-190) x AAA78402 (1-1461)
QY 1 MetMetAsnPhenGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe 20
Db 63 ATGATGAATTTCCAGCCTCCGACCAAGCCTGGCGGGCTCACAGATGATGACTTCTTC 122
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuGlyCysThrLeuAlaIleThrIle 40
Db 123 ATCTTCTTGCTCTTTTCCCATCTTTTCACCGGGGCTTGTGACCCCTGGCCATGCACATC 182
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
Db 183 TGGAGATTTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGCTGCCCTCTTCATTCAC 242
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValIleTyr 80
Db 243 TCCATCTACAGCTGATGCACACCCCTAAGTACACGCGCTGCTACCTGTGGTGTGG 302
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100
Db 303 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTTTTTCATCTCACCCTCATGTGTCTA 362
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGluGlyArgLysIleMetIleArgLeuLeu 120
Db 363 ATCATTCACCTTACTTCTTACTGGCAGATCACAGAGGAAGATTATGATTAAGGCTGCTC 422
QY 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140
Db 423 CATGAGCAGATCATTAATGAGGGCAAAAGATAAATGTTCTGATAGAAAATGATCAAG 482
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160
Db 483 CTGCAGGATATGGAGAGAAACCAACCCAGCTCACTGTTCTGTGAAGAAGAGAGAGTG 542
QY 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
Db 543 GAGCAACAAGGCTTTTGGCATTTGGGGGAAACATGATGGCAGTCTTGACTTGGCATCTAGA 602
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190
Db 603 AGATCAGTTCAGAAGTAATCCCAAGGCC 632

RESULT 6
AAH18131
ID AAH18131 standard; cDNA; 1813 BP.
XX
XX AAH18131;
AC
XX
XX 26-JUN-2001 (first entry)
DT
XX
XX Human cDNA sequence SEQ ID NO:18001.
DE
XX
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.
XX
XX Homo sapiens.
OS
XX
XX EP1074617-A2.
PN
XX
XX 07-FEB-2001.
PD
XX
XX
```



PF 28-JUL-2000; 2000EP-0116126.  
XX  
PR 29-JUL-1999; 99JP-0248036.  
PR 27-AUG-1999; 99JP-0300253.  
PR 11-JAN-2000; 2000JP-0118776.  
PR 02-MAY-2000; 2000JP-0183767.  
PR 09-JUN-2000; 2000JP-0241899.  
XX  
XX (HELI-) HELIX RES INST.  
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;  
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;  
XX  
XX WPI; 2001-318749/34.  
DR  
XX  
PT Primer sets for synthesizing polynucleotides, particularly the 5602  
PT full-length cDNAs defined in the specification, and for the detection  
PT and/or diagnosis of the abnormality of the proteins encoded by the  
PT full-length cDNAs -  
XX  
XX  
PS Claim 8; SEQ ID 18001; 2537pp + CD ROM; English.  
XX  
XX  
CC The present invention describes primer sets for synthesizing 5602  
CC full-length cDNAs defined in the specification. Where a primer set  
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary  
CC to the complementary strand of a polynucleotide which comprises one of  
CC the 5602 nucleotide sequences defined in the specification, where the  
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination  
CC of an oligonucleotide comprising a sequence complementary to the  
CC complementary strand of a polynucleotide which comprises a 5'-end  
CC sequence and an oligonucleotide comprising a sequence complementary to a  
CC polynucleotide which comprises at least 15 nucleotides and the combination of  
CC the 5'-end sequence/3'-end sequence is selected from those defined in  
CC the specification. The primer sets can be used in antisense therapy and  
CC in gene therapy. The primers are useful for synthesizing polynucleotides,  
CC particularly full-length cDNAs. The primers are also useful for the  
CC detection and/or diagnosis of the abnormality of the proteins encoded by  
CC the full-length cDNAs. The primers allow obtaining of the full-length  
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and  
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to  
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632  
CC represent oligonucleotides, all of which are used in the exemplification  
CC of the present invention.  
XX  
SQ Sequence 1813 BP; 489 A; 400 C; 405 G; 519 T; 0 other;  
  
Alignment Scores:  
Pred. No.: 3.5e-108 Length: 1813  
Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0  
  
US-09-895-298A-83 (1-190) x AAH18131 (1-1813)  
QY 1 MetMetAsnPhenGlnProProSerIysAlaTrpArgAlaSerGlnMetMetThrPhePhe 20  
DB 451 ATGATGAAATTCACAGCTCCGAGCAAAAGCCGCGGCGCTCACAGATGATGACTTCTTC 510  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 511 ATCTCTGTGCTCTTTTCCATCCTTCACCGGGGTCTGTGCACCCCTGCGCATCACCATC 570  
QY 41 TrpArgLeuLeuProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 571 TGGAGATGGAAGCCTTCACAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCAATTAC 630  
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
DB 631 TCCATCTACAGCTGGATGACACACCTAAGTACACGCGCTGCTACCTGTGGTTGTTGG 690

QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
DB 691 ATCTATCGGAACCTCATTTGGGAAGTGTGCACCTCTTTTCATCCTCACCCCTCATTTGTGCTA 750  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlyArgGlyIleMetIleArgLeuLeu 120  
DB 751 ATCATCACCTATCTTTTACGTGGCAGATCACAGAGGGAAGATATATGATAAGCGCTC 810  
QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140  
DB 811 CATGACAGATCATTTAATGACGGCAAAAGATATAATGTTCTGTATGAAAAATTGATCAAG 870  
QY 141 LeuGlnAspMetGlyLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160  
DB 871 CTGCAGCATATGACAGAAAGCAAAACCCCACTCACTTGTCTGAAAAGAGAGAGGTG 930  
QY 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180  
DB 931 GAGCAACAAGCGCTTTTTCGATTTGGGGGGAACATGATGCGAGTCTGACCTTGCATCTAGA 990  
QY 181 ArgSerValGlnGlnGlyAsnProArgAla 190  
DB 991 AGATCAGTTCAAGAAAGTAATCAAGAGGCC 1020  
  
RESULT 7  
AAAF82462  
ID AAF82462 standard; cDNA; 1960 BP.  
XX  
AC AAF82462;  
XX  
DT 29-JUN-2001 (first entry)  
XX  
DE Human CASB6411-related cDNA #1.  
XX  
KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
KW ovarian cancer; colon cancer; autoimmune disease; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 1..1317  
FT /tag= a  
FT /partial  
FT /note= "this sequence does not contain a start codon"  
XX  
XX  
PN WO200123417-A2.  
XX  
PD 05-APR-2001.  
XX  
PF 27-SEP-2000; 2000WO-EP09500.  
XX  
PR 30-SEP-1999; 99GB-0023154.  
PR 07-JUL-2000; 2000GB-0016839.  
XX  
PA (SMK ) SMITHKLINE BEECHAM BIOLOGICALS.  
XX  
PI Vinals De Bassols YC;  
XX  
DR WPI; 2001-316133/33.  
DR P-PSDB; AAB83081.  
XX  
XX  
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for  
PT prophylactic and therapeutic treatment of cancers, particularly ovarian  
PT and colon cancers, autoimmune diseases and related conditions -  
XX  
XX  
PS Claim 32; Page 65-66; 95pp; English.  
XX  
CC The present sequence is provided in a specification relating  
CC to CASB6411 polypeptides comprising a sequence having at least 70%  
CC identity to a sequence of 460 or 154 amino acids fully defined in  
CC the specification. CASB6411 polypeptides and polynucleotides are  
CC useful for treating a subject by immunoprophylaxis or therapy.  
CC The CASB6411 polypeptides are useful in diagnostics, and as



CC vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases and related conditions. CASB641 polypeptides are also useful for the structure-based design of agonists, antagonists or inhibitors of the polypeptide.

XX Sequence 1960 BP; 515 A; 439 C; 447 G; 559 T; 0 other;

## Alignment Scores:

Pred. No.:	3.91e-108	Length:	1960
Score:	1002.00	Matches:	190
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	22	Gaps:	0

US-09-895-298A-83 (1-190) x AAF82462 (1-1960)

```
QY 1 MetMetAsnPhgInProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhe 20
    |||||||
Db 745 ATGATGAAATTCAGCCTCCGAGCAAGCCTGGCGGCTCAGAGATGATGACTTCTTC 804

QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40
    |||||||
Db 805 ATCTTCTTGCTCTTTTCCATCTTTCACCGGGGCTTGTGCACCCCTGGCCATCACCATC 864

QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
    |||||||
Db 865 TGGAGATTGAAGCCTTCAGCTGACGTGCGCCCTTTCAGAGTGTGCTCTTCATTTCAC 924

QY 61 SerIleTyrSerTrpIleAspThrIleSerThrArgProGlyTyrLeuTrpValValTrp 80
    |||||||
Db 925 TCCATCTACAGCTGGATCGACACCCCTAAGTACACGCGCTGCTGCTGCTGCTGCTG 984

QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100
    |||||||
Db 985 ATCTATCGGAACCTCATGTGGAAGTGTGCACCTCTTTTCATCCACCCCTCATTTGTGCTG 1044

QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120
    |||||||
Db 1045 ATCATCACCTATCTTACTGCGAGATCACAGAGGAAGAAAGATTATGATTAAGGCTGCTC 1104

QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140
    |||||||
Db 1105 CATGAGCAGATCAATTAATGAGGGCAAGATAAATGTTCTGTGATAGAAAATTTGATCAAG 1164

QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGluArgArgGlyVal 160
    |||||||
Db 1165 CTGCAGGATATGGAGAAAGAAAGCAACCCAGCTCATTGTTCTGGAAGAGAGAGAGTG 1224

QY 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
    |||||||
Db 1225 GAGCAACAAGGCTTTTTCATTTGGGGGAACATGATGCGAGTCTTGACTTGCAGATCTAGA 1284

QY 181 ArgSerValGlnGlnGlyLysProArgAla 190
    |||||||
Db 1285 AGATCAGTTCAAGAAAGGTAATCCAAAGGGCC 1314

RESULT 8
ID AAA64684 standard; cDNA; 2243 BP.
XX
AC AAA64684;
XX
DT 02-JAN-2001 (first entry)
XX
DE cDNA encoding a human leukocyte and blood related protein (LBAP).
XX
KW Human; leukocyte and blood related protein; LBAP; arteriosclerosis;
KW cell proliferative disorder; actinic keratosis; atherosclerosis;
KW buritis; cirrhosis; hepatitis; mixed connective tissue disease; MCTD;
KW myelofibrosis; paroxysmal nocturnal hemoglobinuria; cancer;
KW adenocarcinoma; leukemia; lymphoma; melanoma; myeloma; sarcoma;
```

KW teratocarcinoma; autoimmune disorder; inflammatory disorder; acquired immunodeficiency syndrome; AIDS; Addison's disease; adult respiratory distress syndrome; allergy; ankylosing spondylitis; amyloidosis; anaemia; asthma; autoimmune haemolytic anaemia; infection; Werner syndrome; haemodialysis; extracorporeal circulation; trauma; ss.

XX Homo sapiens.

Key	Location/Qualifiers
FT CDS	109..1272
FT	/tag= a
FT	/product= "leukocyte and blood related protein (LBAP)"
FT	109..261
FT	/tag= b

XX WO200052161-A2.

XX 08-SEP-2000.

XX 29-FEB-2000; 2000WO-US05153.

XX 01-MAR-1999; 99US-0122080.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Yue H, Hillman JL, Lu DAM, Baughn MR, Tang YT, Azimzal Y;

XX WPI; 2000-587310/55.

XX P-PSDB; AAB08764.

PT Leukocyte and blood associated proteins and polynucleotides encoding them, useful for diagnosis, treatment and prevention of autoimmune/inflammatory disorders and cell proliferative disorders including cancer -

XX Claim 4; Page 68-69; 70pp; English.

XX The present sequence encodes a human leukocyte and blood related protein, designated LBAP. LBAP polynucleotides and polypeptides are useful for treating or preventing a disorder associated with decreased expression or activity of LBAP including a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, buritis, CC cirrhosis, hepatitis, mixed connective tissue disease (MCTD), CC myelofibrosis, paroxysmal nocturnal hemoglobinuria, etc., cancers CC including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, CC sarcoma, teratocarcinoma and in particular cancers of the adrenal CC gland, bladder, bone, bone marrow, brain, breast, cervix, etc., and CC an autoimmune/inflammatory disorder such as acquired immunodeficiency CC syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, CC allergies, ankylosing spondylitis, amyloidosis, anaemia, asthma, CC atherosclerosis, autoimmune haemolytic anaemia, etc., Werner syndrome, CC complications of cancer, haemodialysis, and extracorporeal circulation, CC viral, bacterial, fungal, parasitic, protozoan, and helminthic CC infections, and trauma.

XX Sequence 2243 BP; 602 A; 500 C; 520 G; 621 T; 0 other;

## Alignment Scores:

Pred. No.:	4.75e-108	Length:	2243
Score:	1002.00	Matches:	190
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	21	Gaps:	0

US-09-895-298A-83 (1-190) x AAA64684 (1-2243)

```
QY 1 MetMetAsnPhgInProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhe 20
    |||||||
Db 700 ATGATGAATTTCCAGCCTCCGAGCAAGCCTGGCGGCTCAGAGATGATGACTTCTTC 759

QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40
    |||||||
```

Db 760 ATCTTCTGCTCTTTTCCCATCTTCCACCGGGGCTCTGTGTGACACCTCGCCATCACCATC 819  
QY 41 TTPARGLEULYSEROSERIALASPYSGLYPHOPHEARGLYLEUPHLEUHPHEILEHIS 60  
Db 820 TGGAGATTGAAGCCTTCAGCTGACGTGTGCCCTTTTCGAGGCTGTGCTCTCTTCATTCCAC 879  
QY 61 SerIleYrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTPValValTrp 80  
Db 880 TCCATCTACAGCGGATCGACACCCCTAAGTACACGGCTGCTACCTGTGGGTTGTTGG 939  
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrLeuIleValLeu 100  
Db 940 ATCTATCGAACCCTCATTTGGAAGTGTGCACCTCTTTTCATCTCCACCCCTCATTTGTGCTA 999  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGluGluArgLysIleMetIleArgLeuLeu 120  
Db 1000 ATCATCACCTATCTTACTGCGACAGATCACAGAGGGAAGATTATGATTAAGGCTGCTC 1059  
QY 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140  
Db 1060 CATGAGCAGATCATTAATGAGGGCAAGATTAATGTTCTGTATAGAAAAATTGATCAAG 1119  
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160  
Db 1120 CTGCAGGATATGGAGAGAAGAAACCCACCTCCTGTTCTGGAAAGAGAGAGAGGTG 1179  
QY 161 GluGlnGlnGlyPheLeuHisLeuGluHisAspGlySerLeuAspLeuArgSerArg 180  
Db 1180 GAGCAACAAGGCTTTTGTGCTTTGGGGGAACATGATGCAGTCTTGACCTTGCATCTAGA 1239  
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190  
Db 1240 AGATCAGTTCAAGAGTAATCCAAAGGCC 1269  
RESULT 9  
AAF82460  
ID AAF82460 standard; cDNA; 2407 BP.  
XX AAF82460;  
AC AAF82460;  
XX 29-JUN-2001 (first entry)  
DT Human CASB6411 cDNA.  
DE Human CASB6411 cDNA.  
XX  
KM Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
KW ovarian cancer; colon cancer; autoimmune disease; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 382..1764  
FT /\*tag= a  
FT /product= "CASB6411"  
XX  
PN WO200123417-A2.  
XX  
PD 05-APR-2001.  
XX  
PF 27-SEP-2000; 2000MO-EP09500.  
XX  
PR 30-SEP-1999; 99GB-0023154.  
PR 07-JUL-2000; 2000GB-0016839.  
XX  
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.  
XX  
PI Vinals De Bassols YC;  
XX  
DR WPI; 2001-316133/33.  
DR P-PSDB; AAB83079.  
XX  
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for  
PT prophylactic and therapeutic treatment of cancers, particularly ovarian  
PT and colon cancers, autoimmune diseases and related conditions

XX  
PS Claim 11; Page 63-64; 95pp; English.  
XX  
CC The present sequence encodes human CASB6411 polypeptide. The  
CC invention relates to CASB6411 polypeptides comprising a sequence  
CC having at least 70% identity to a sequence of 460 or 154 amino acids  
CC fully defined in the specification. CASB6411 polypeptides and  
CC polynucleotides are useful for treating a subject by immunoprophylaxis  
CC or therapy. The CASB6411 polypeptides are useful in diagnostics, and  
CC as vaccines for prophylactic and therapeutic treatment of cancers,  
CC particularly ovarian and colon cancers, autoimmune diseases and related  
CC conditions. CASB6411 polypeptides are also useful for the  
CC structure-based design of agonists, antagonists or inhibitors of the  
CC polypeptide. The present sequence may be alternatively spliced to  
CC generate a sequence encoding a truncated CASB6411 protein.  
XX  
SQ Sequence 2407 BP; 635 A; 557 C; 546 G; 669 T; 0 other;  
  
Alignment Scores:  
Pred. No.: 5.26e-108 Length: 2407  
Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0  
  
US-09-895-298A-83 (1-190) x AAF82460 (1-2407)  
QY 1 MetMetAsnPheGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhe 20  
Db 1192 ATGATGAATTTCCAGCCTCCGAGCAAAAGCCCTGGCGGCTCAGATGACCTTCTTC 1251  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
Db 1252 ATCTTCTGCTCTTTTCCCATCCTTCACCGGGGCTGTGTGCACCTGGCCATCACCATC 1311  
QY 41 TTPARGLEULYSEROSERIALASPYSGLYPHOPHEARGLYLEUPHLEUHPHEILEHIS 60  
Db 1312 TGGAGATTGAAGCCTTCAGCTGACGTGTGGCCCTTTTCGAGGTGTGCTCTTCATTCCAC 1371  
QY 61 SerIleYrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTPValValTrp 80  
Db 1372 TCCATCTACAGCTGGATCGACACCCCTAAGTACACGGCTGCTACCTGTGGGTTGTTGG 1431  
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrLeuIleValLeu 100  
Db 1432 ATCTATCGAACCCTCATTTGGAAGTGTGCACCTCTTTTCATCTCCACCCCTCATTTGTGCTA 1491  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGluGluArgLysIleMetIleArgLeuLeu 120  
Db 1492 ATCATCACCTATCTTACTGCGACAGATCACAGAGGGAAGATTATGATTAAGGCTGCTC 1551  
QY 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140  
Db 1552 CATGAGCAGATCATTAATGAGGGCAAGATTAATGTTCTGTATAGAAAAATTGATCAAG 1611  
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160  
Db 1612 CTGCAGGATATGGAGAGAAGCAAAACCCACGCTCCTGTTCTGGAAAGAGAGAGGTG 1671  
QY 161 GluGlnGlnGlyPheLeuHisLeuGluHisAspGlySerLeuAspLeuArgSerArg 180  
Db 1672 GAGCAACAAGGCTTTTGTGATTTGGGGGAACATGATGCAGTCTTGACTTGCATCTAGA 1731  
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190  
Db 1732 AGATCAGTTCAAGAAAGTAATCCAAAGGCC 1761  
RESULT 10  
AAF82461  
ID AAF82461 standard; cDNA; 2521 BP.  
XX  
AC AAF82461;

```
XX 29-JUN-2001 (first entry)
DT
XX Alternately spliced human CASB6411 cDNA encoding truncated protein.
DE
XX
XX Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;
KW ovarian cancer; colon cancer; autoimmune disease; isoform;
KW alternative splicing; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH CDS 382..846
FT /tag=a
FT /product="truncated CASB6411"
XX
XX WO200123417-A2.
PN
XX
XX 05-APR-2001.
PD
XX
XX 27-SEP-2000; 2000WO-EP09500.
PF
XX
XX 30-SEP-1999; 99GB-0023154.
PR
XX 07-JUL-2000; 2000GB-0016839.
PR
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
PA
XX
XX Vinals De Bassols YC;
PI
XX
XX WPI; 2001-316133/33.
DR
XX P-PSDB; AAB83080.
DR
XX
XX Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
PT prophylactic and therapeutic treatment of cancers, particularly ovarian
PT and colon cancers, autoimmune diseases and related conditions
XX
XX Claim 11; Page 64-65; 95pp; English.
PS
XX
XX The present sequence encodes a truncated CASB6411 polypeptide. It
CC is generated by alternative splicing of the full length human cDNA
CC sequence of CASB6411. The invention relates to CASB6411 polypeptides
CC comprising a sequence having at least 70% identity to a sequence of
CC 460 or 154 amino acids fully defined in the specification. CASB6411
CC polypeptides and polynucleotides are useful for treating a subject by
CC immunoprophylaxis or therapy. The CASB6411 polypeptides are useful in
CC diagnostics, and as vaccines for prophylactic and therapeutic treatment
CC of cancers, particularly ovarian and colon cancers, autoimmune diseases
CC and related conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
CC polypeptide.
CC
SQ Sequence 2521 BP; 662 A; 583 C; 583 G; 693 T; 0 other;

Alignment Scores:
Pred. No.: 5.62e-108 Length: 2521
Score: 1002.00 Matches: 190
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 22 Gaps: 0

US-09-895-298A-83 (1-190) x AAF82461 (1-2521)

QY 1 MetMetAsnPhgInProSerLysAlaTrpArgAlaSerGlnMetMetThrPhephe 20
DB 1306 ATGATGAAATTCAGCCCTCCGAGCAAAAGCTGGCGGCTCACAGATGATGACTTCTTC 1365
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40
DB 1366 ATCTTCTTGTCTTTTCCATCCTTCACCGGGGTCTTGTGCACCCCTGGCCATCACCATC 1425
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
|||||
```

```
DB 1426 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGTCTGCTCTTCATTTCAC 1485
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValIleTrp 80
DB 1486 TCCATCTACAGCTGGATCGACACCTTAAGTACACGGCTGGCTTACCTGTGGTGTGG 1545
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100
DB 1546 ATCTATCGGAACCTCATTTGGAAGTGTGACTTCTTTTCATCTCACCCTCATTTGTGCTA 1605
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120
DB 1606 ATCATCACCTATCTTTACTGGCAGATCACAGAGGAAGGAATTATGATTAAGGCTGCTC 1665
QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140
DB 1666 CATGAGCAGATCATTAATGAGGGCAAGATAAATGTTCTGTAGATAAATTGATCAAG 1725
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGluArgGluVal 160
DB 1726 CTGACGATATGAGAGAAGAAAGCAACCCAGCTCACTTGTCTGGAAGAAGAGAGAGTGTG 1785
QY 161 GluGlnGlnGlyPheLeuHisLeuGlnGlyLysAspLysSerLeuAspLeuArgSerArg 180
DB 1786 GAGCAACAAGCCTTTTTCATTTGGGGGAACATGATGCGACGCTTGACTTGGCATCTAGA 1845
QY 181 ArgSerValGlnGlyLysProArgAla 190
DB 1846 AGATCAGTTCAGAGAAGTAATCCAAAGGCC 1875

RESULT 11
ABV22463
ID ABV22463 standard; cDNA; 1194 BP.
XX
XX AC ABV22463;
XX
XX 13-SEP-2002 (first entry)
DT
XX
XX Human prostate expression marker cDNA 22454.
DE
XX
XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200160860-A2.
PN
XX
XX 23-AUG-2001.
PD
XX
XX 20-FEB-2001; 2001WO-US05171.
PF
XX
XX 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Schlegel R, Endege WO, Monahan JE;
XX
XX WPI; 2001-662795/76.
DR
XX
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer
XX
XX Claim 1; Page 3912; 11750pp; English.
PS
XX
XX The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
```

CC (a) assessing whether a patient is afflicted with prostate cancer;  
CC (b) monitoring the progression of prostate cancer in a patient;  
CC (c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;  
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound;  
CC (g) determining whether prostate cancer has metastasized in a patient;  
CC (h) assessing the aggressiveness or indolence of prostate cancer in a patient;  
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX  
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;  
  
Alignment Scores:  
Pred. No.: 1.19e-102 Length: 1194  
Score: 953.00 Matches: 186  
Percent Similarity: 97.89% Conservative: 0  
Best Local Similarity: 97.89% Mismatches: 4  
Query Match: 95.11% Indels: 1  
DB: 23 Gaps: 0  
  
US-09-895-298A-83 (1-190) x ABV22463 (1-1194)  
QY 1 MetMetasnpheGlnProProSerIysAlaTrpArgAlaSerGlnMetMetThrphe 20  
DB 531 ATGATGAAATTTCCAGCCTTCGAGCAAAAGCCCTGGCGGCTCACAGATGATGATCTTCTTC 590  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuGlySerThrLeuAlaIleThrIle 40  
DB 591 ATCTTCTGCTCTTTTCCCATCTTCACCGGGGTCTGTGACCCCTGGCCATCACCATC 650  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 651 TGGAGATTGAAGCCTTCACCTGACTGTGGCCCTTTTGCAGGCTGCTCTTCATTCAC 710  
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
DB 711 TCCATCTACAGCTGGATCGACACCTTAAGTACAGCGGCTGCTGCTGCTGCTGCTTGG 770  
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
DB 771 ATCTATCGGAACCTCATTTGAAGTGTGCACCTTTTCATCTTCACCCCTCATTTGCTA 830  
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgGlyIleMetIleArgLeuLeu 120  
DB 831 ATCATCACCTATCTTACTGGCAGATCACAGAGGGAAGATTATGATTAAGGCTGCTC 890  
QY 121 HisGlnGlnIleLeuAsnGlnGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140  
DB 891 CATGACGAGATCATTAATGAGGCAAAAGATAAATGTCTGATAGAAAAATTGATCAAG 950  
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValLeuGlnArgGluVal 160  
DB 951 CTGACGATATGAGAGAAAGCAAAACCCAGC-TCACCTTACTGGAAGAGAGAGGCTG 1009  
QY 161 GlnGlnGlnGlyPheLeuHisLeuGlnHisAspGlySerLeuAspLeuArgSerArg 180  
DB 1010 GAGCAACAAGGCTTATTCATTAAGGGGACATGATGCGACGTCTTGACTGCGATCTAGA 1069  
QY 181 ArgSerValGlnGlnGlyAsnProArgAla 190  
DB 1070 CGATCAGTTCAAGAAAGTAAATCCAAAGGCC 1099  
  
RESULT 12  
ABV25683  
ID ABV25683 standard; cDNA; 1194 BP.  
XX  
AC ABV25683;  
XX  
DT 16-SEP-2002 (first entry)  
XX

DE Human prostate expression marker cDNA 25674.  
XX  
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200160860-A2.  
XX  
PD 23-AUG-2001.  
XX  
PF 20-FEB-2001; 2001WO-US05171.  
XX  
PR 17-FEB-2000; 2000US-183319P.  
PR 16-MAR-2000; 2000US-189862P.  
PR 25-MAY-2000; 2000US-207454P.  
PR 09-JUN-2000; 2000US-211314P.  
PR 18-JUL-2000; 2000US-219007P.  
PR 13-DEC-2000; 2000US-255281P.  
XX  
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX  
PI Schlegel R, Endege WO, Monahan JE;  
XX  
DR WPI; 2001-662795/76.  
XX  
PT Novel isolated nucleic acid molecule associated with cancerous state of  
PT prostate cells and correlating with presence of prostate cancer, useful  
PT for detecting presence of prostate cancer, stage of prostate cancer  
XX  
PS Claim 1; Page 5146-5147; 11750pp; English.  
XX  
CC The invention relates to an isolated nucleic acid molecule (I) comprising  
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
CC specification or its complement. (I) is useful for:  
CC (a) assessing whether a patient is afflicted with prostate cancer;  
CC (b) monitoring the progression of prostate cancer in a patient;  
CC (c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;  
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound;  
CC (g) determining whether prostate cancer has metastasized in a patient;  
CC (h) assessing the aggressiveness or indolence of prostate cancer in a patient;  
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX  
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;  
  
Alignment Scores:  
Pred. No.: 1.19e-102 Length: 1194  
Score: 953.00 Matches: 186  
Percent Similarity: 97.89% Conservative: 0  
Best Local Similarity: 97.89% Mismatches: 4  
Query Match: 95.11% Indels: 1  
DB: 23 Gaps: 0  
  
US-09-895-298A-83 (1-190) x ABV25683 (1-1194)  
QY 1 MetMetasnpheGlnProProSerIysAlaTrpArgAlaSerGlnMetMetThrphe 20  
DB 531 ATGATGAAATTTCCAGCCTTCGAGCAAAAGCCCTGGCGGCTCACAGATGATGATCTTCTTC 590  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuGlySerThrLeuAlaIleThrIle 40  
DB 591 ATCTTCTGCTCTTTTCCCATCTTCACCGGGGTCTGTGACCCCTGGCCATCACCATC 650  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 651 TGGAGATTGAAGCCTTCACCTGACTGTGGCCCTTTTGCAGGCTGCTCTTCATTCAC 710  
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80

```
|||||
Db 711 TCATCTACAGCTGGATCGACGCCCTAGTACACGCCCTGCTACCTGTGTGG 770
QY 81 IletyrArgAsnLeuIleGlySerValHisPhePheIleuThrLeuIleValleu 100
Db 771 ATCTATCGAAGCTCATTTGAGGTGTGCACTCTTTTTCATCCTCACCCCTCATGTGCTA 830
QY 101 IletleThrTyrLeuTyrTrpGlnIleThrGluGlyArgGlyIleMetIleArgLeu 120
Db 831 ATCATACCTATCTTACTTGCGAGATCACAGAGGAAGATTATGATTAAGCTGCTC 890
QY 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140
Db 891 CATGAGCAGATCATTAATGAGGCAAGATAAATGTTCTCGATAGAAAATTATCAAG 950
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValleuGluArgGluVal 160
Db 951 CTGAGGATATGAGAGAAAGCAACCCAGC-TCACCTTGTACTGAAAGAGAGAGTGT 1009
QY 161 GluGlnGlnGlyPheLeuHisLeuGlyIleHisAspGlySerLeuAspLeuArgSerArg 180
Db 1010 GAGCAACAAGCCTTATTTGCAATTAAGCGGACATGATGGCAGTCTTGACTTGGATCTAGA 1069
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190
Db 1070 CGATCAGTTCACAAGAGTAATCCAAAGGCC 1099

RESULT 13
ABV28278
ID ABV28278 standard; cDNA; 1194 BP.
XX
AC ABV28278;
XX
DT 16-SEP-2002 (first entry)
XX
DE Human prostate expression marker cDNA 28269.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
XX
OS Homo sapiens.
XX
PN WO200160860-A2.
XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX
DR WPI; 2001-662795/76.
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 5881-5882; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
```

```
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;

Alignment Scores:
Pred. No.: 1,19e-102 Length: 1194
Score: 953.00 Matches: 186
Percent Similarity: 97.89% Conservative: 0
Best Local Similarity: 97.89% Mismatches: 4
Query Match: 95.11% Indels: 1
DB: 23 Gaps: 0

US-09-895-298a-83 (1-190) x ABV28278 (1-1194)
QY 1 MetMetAsnPheGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe 20
Db 531 ATGATGAATTTCCAGCCTCCGACCAAGCCTGGCGGCTCAGATGATGACTTCTTC 590
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuGlyCysThrLeuAlaIleThrIle 40
Db 591 ATCTTCTTGCTCTTTTCCATCTTACACGGGGGTCTGTGTGACCCCTGGCCATACCATC 650
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
Db 651 TGAGATTTGAAGCCTTCAGCTGACTGTGGCCTTTTCGAGAGTGTGCCCTCTTCATTTCAC 710
QY 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValIleTrp 80
Db 711 TCATCTACAGCTGGATCGACACCCCTAAGTACACGCGCTGCTACCTGTGGTGTGG 770
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleuThrLeuIleValleu 100
Db 771 ATCTATCGAAGCTCATTTGAGAGTGTGCACTCTTTTTCATCCTCACCCCTCATGTGCTA 830
QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGluGlyArgLysIleMetIleArgLeu 120
Db 831 ATCATCACCTATCTTACTTGCGAGATCACAGGGAAGAAATTATGATTAAGCTGCTC 890
QY 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheLeuIleGluLysLeuIleLys 140
Db 891 CATGAGCAGATCATTAATGAGGCAAGATAAATGTTCTCGATAGAAAATTATCAAG 950
QY 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerLeuValleuGluArgGluVal 160
Db 951 CTGAGGATATGAGAGAAAGCAACCCAGC-TCACCTTGTACTGAAAGAGAGAGTGT 1009
QY 161 GluGlnGlnGlyPheLeuHisLeuGlyIleHisAspGlySerLeuAspLeuArgSerArg 180
Db 1010 GAGCAACAAGCCTTATTTGCAATTAAGCGGACATGATGGCAGTCTTGACTTGGATCTAGA 1069
QY 181 ArgSerValGlnGluGlyAsnProArgAla 190
Db 1070 CGATCAGTTCACAAGAGTAATCCAAAGGCC 1099

RESULT 14
AAL18591
ID AAL18591 standard; cDNA; 470 BP.
XX
AC AAL18591;
XX
DT 07-DEC-2001 (first entry)
XX
DE Human breast cancer expressed polynucleotide 11048.
XX
KW Human; breast cancer; cell marker; cytostatic; ss.
```

```
XX OS Homo sapiens.
XX PN WO200151628-A2.
XX PD 19-JUL-2001.
XX PF 10-JAN-2001; 2001WO-US00798.
XX PR 14-JAN-2000; 2000US-0176077.
XX PR 14-MAR-2000; 2000US-0189167.
XX PR 24-MAR-2000; 2000US-0192099.
XX PR 29-MAR-2000; 2000US-0193480.
XX PR 15-MAY-2000; 2000US-0205230.
XX PR 09-JUN-2000; 2000US-0211315.
XX PR 25-JUL-2000; 2000US-0220534.
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Lillie J, Xu Y, Wang Y, Steinmann K;
XX DR WPI; 2001-451856/48.
XX PT New peptide useful as a marker for the diagnosis of breast cancer -
XX PS Claim 1; Page 1968; 3695pp; English.
XX CC The invention relates to human breast cancer expressed polynucleotides
CC (AAL07544-AAL26789) and methods of assessing whether a patient is
CC afflicted with breast cancer by examining the correlation between the
CC expression of certain markers and the cancerous state of breast cells.
CC The polynucleotides and encoded polypeptides are potential markers for
CC detecting, diagnosing, monitoring, characterising treating and
CC potentially preventing breast cancer. The polynucleotides and encoded
CC polypeptides are also useful for isolating compounds with cytostatic
CC activity.
XX SQ Sequence 470 BP; 144 A; 92 C; 116 G; 118 T; 0 other;

Alignment Scores:
Pred. No.: 7.15e-64 Length: 470
Score: 620.00 Matches: 120
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 61.88% Indels: 0
DB: 22 Gaps: 0

US-09-895-298A-83 (1-190) x AAL18591 (1-470)
OY 71 ThrArgProGlyTyrLeuTrpValAlaTripletYrArgAsnLeuIleGlySerValHis 90
DB 5 ACACGGCCTGGCTACCTGTGGTGTGGATCTATCGAACCCTCATTTGGAAGTGCAC 64
OY 91 PhePhePheIleLeuThrLeuIleValLeuIleIleThrTyrLeuTyrTrpGlnIleThr 110
DB 65 TTCTTTTTCATCCTCACCCCTCATTTGTCTAATCATCATCTATCTTTACTGGCAGATCACA 124
OY 111 GluGlyArgIleMetIleArgLeuLeuHisGluGlnIleIleAsnGluGlyLysASP 130
DB 125 GAGGGAAGAGATTATGATTAAGGCTGCTCATGACAGATCATTAATGAGGGCAAGAT 184
OY 131 LysMetPheLeuIleGluLysLeuIleLysLeuGlnAspMetGluLysIleAsnPro 150
DB 185 AAAATGTTCTGATAGAAAATTGATCAAGCTGCAGAGATATGAGAAAGCAAAACCCC 244
OY 151 SerSerLeuValLeuGluArgArgGluValGluGlnGlnGlyPheLeuHisLeuGlyGlu 170
DB 245 AGCTCACTGTCTCGAAGAGAGAGAGGTGAGCAACAAGCCTTTTTCATTTGGGGGAA 304
OY 171 HisAspGlySerLeuAspLeuArgSerArgArgSerValGlnGluGlyAsnProArgAla 190
DB 305 CATGATGGCAGACTTGGACTTGCATCTAGAGATCAGTTCAAGAAAGTAAATCCAAGGCC 364
```

```
RESULT 15
AAL09919
ID AAL09919 standard; cDNA; 501 BP.
XX AC AAL09919;
XX DT 07-DEC-2001 (first entry)
XX DE Human breast cancer expressed polynucleotide 2376.
XX KW Human; breast cancer; cell marker; cytostatic; ss.
XX OS Homo sapiens.
XX PN WO200151628-A2.
XX PD 19-JUL-2001.
XX PF 10-JAN-2001; 2001WO-US00798.
XX PR 14-JAN-2000; 2000US-0176077.
XX PR 14-MAR-2000; 2000US-0189167.
XX PR 24-MAR-2000; 2000US-0192099.
XX PR 29-MAR-2000; 2000US-0193480.
XX PR 15-MAY-2000; 2000US-0205230.
XX PR 09-JUN-2000; 2000US-0211315.
XX PR 25-JUL-2000; 2000US-0220534.
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Lillie J, Xu Y, Wang Y, Steinmann K;
XX DR WPI; 2001-451856/48.
XX PT New peptide useful as a marker for the diagnosis of breast cancer -
XX PS Claim 1; Page 455; 3695pp; English.
XX CC The invention relates to human breast cancer expressed polynucleotides
CC (AAL07544-AAL26789) and methods of assessing whether a patient is
CC afflicted with breast cancer by examining the correlation between the
CC expression of certain markers and the cancerous state of breast cells.
CC The polynucleotides and encoded polypeptides are potential markers for
CC detecting, diagnosing, monitoring, characterising treating and
CC potentially preventing breast cancer. The polynucleotides and encoded
CC polypeptides are also useful for isolating compounds with cytostatic
CC activity.
XX SQ Sequence 501 BP; 147 A; 101 C; 128 G; 122 T; 3 other;

Alignment Scores:
Pred. No.: 4.02e-63 Length: 501
Score: 614.00 Matches: 119
Percent Similarity: 99.17% Conservative: 0
Best Local Similarity: 99.17% Mismatches: 1
Query Match: 61.28% Indels: 0
DB: 22 Gaps: 0

US-09-895-298A-83 (1-190) x AAL09919 (1-501)
OY 71 ThrArgProGlyTyrLeuTrpValAlaTripletYrArgAsnLeuIleGlySerValHis 90
DB 36 ACACGGCCTGGCTACCTGTGGTGTGGATCTATCGAACCCTCATTTGGAAGTGCAC 95
OY 91 PhePhePheIleLeuThrLeuIleValLeuIleIleThrTyrLeuTyrTrpGlnIleThr 110
DB 96 TTCTTTTTCATCCTCACCCCTCATTTGTGTAATCATCATCTTACTTACGAGATCACA 155
OY 111 GluGlyArgIleMetIleArgLeuLeuHisGluGlnGlnGlyPheLeuHisLeuGlyLysASP 130
DB 156 GAGGGAAGAGATTATGATTAAGGCTGCTCATGACAGATCATTAATGAGGGCAAGAT 215
OY 131 LysMetPheLeuIleGluLysLeuIleLysLeuGlnAspMetGluLysIleAsnPro 150
```

|||||  
Db 216 AAAATGTTCCCTGATAGAAAAATGATCAAGCTGCAGGATATGAGAAAGCAACCCC 275  
QY 151 SerSerLeuValLeuGluArgArgGluValGluGlnGlnGlyPheLeuHisLeuGlyGlu 170  
Db 276 AGCTCACTTGTTCTGAAAGAGAGAGGTGAGACACAAGGCTTTTGCATTGGGGGAA 335  
QY 171 HisAspGlySerLeuAspLeuArgSerArgSerValGlnGlyAsnProArgAla 190  
Db 336 CATGATGGCAGCTTGACTTGCGATCTAGANATCAGTTCAAGAAGTAAATCCAAGGGCC 395

Search completed: November 9, 2002, 04:48:43  
Job time : 303 secs



**THIS PAGE BLANK (USPTO)**